Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2018 | Image of the Month

Advantage of ¹⁸F-PSMA-1007 over ⁶⁸Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

Authors: Kambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, Michael Schäfers, Lars Stegger, Martin Bögemann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2018

Excerpt

…

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3711-7.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678–88. https://doi.org/10.1007/s00259-016-3573-4.CrossRefPubMed

Title: Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion
Authors: Kambiz Rahbar
Matthias Weckesser
Hojjat Ahmadzadehfar
Michael Schäfers
Lars Stegger
Martin Bögemann
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-3952-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Advantage of ¹⁸F-PSMA-1007 over ⁶⁸Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2018

11C–acetate PET/CT: a potential alternative of transcranial biopsy for grading cerebral gliomas

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Assessment of alteration in liver 18F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model